The Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.
Merck’s cardiopulmonary pipeline is poised to deliver eight potential approvals over the next eight years, bolstering the company’s pipeline and revenue.
Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C. Data from KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)1 and asundexian, an investigational oral Factor XIa inhibitor2 will be presented at the meeting. These data highlight Bayer’s ongoing commitment to patients with cardiovascular (CV) and kidney diseases.
The U.S. Food and Drug Administration approved a 2 mg dose of Novo Nordisk’s Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
The Janssen Pharmaceutical Companies of Johnson & Johnson presented data from the Phase 3 VOYAGER PAD study which showed Xarelto (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization compared to aspirin alone regardless of whether it was the first, second, third or subsequent event.
The European Commission granted Amarin Corporation Plc’s fish-oil derived heart drug Vazkepa marketing authorization in the European Union, the drugmaker said on March 30.
When it comes to matters of heart health, no amount of exercise is too much, scientists said regarding research that debunks the myth that high levels of vigorous physical activity might not always be beneficial.
Grünenthal agreed to acquire the European rights (excluding Spain and the UK) to AstraZeneca’s Crestor (rosuvastatin) and its associated brands for a total consideration of up to $350 million.
FibroGen Provides More Support for Roxadustat in Anemia Associated with Kidney Disease Published: Oct. 26, 2020 By Mark Terry BioSpace FibroGen presented data from two pooled analyses from its roxadustat global […]
